Janux Therapeutics, Inc. Overview
JANX market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
JANX price chart · 1M
- O
- 16.34
- H
- 16.98
- L
- 16.34
- C
- 16.67
- Vol
- 13,117.00
Daily history from Jun 11, 2021
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $16.34
- Previous Close
- $16.04
- Day High
- $16.98
- Day Low
- $16.34
- 52 Week High
- $35.24
- 52 Week Low
- $12.14
- 7 Day Return
- -4.72%
- 30 Day Return
- -7.00%
- 90 Day Return
- +1.55%
- 1 Year Return
- -41.87%
- Daily Notional Volume
- $218.6K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.43 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -294.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.12 – $35.34 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.1B · P/B 3.02 · P/S 46.31.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured